Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 15/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19564568 | 1.00 | SLC6A9 (0.47) | SLC6A9SLC6A4HRH3GPR88 | |
| SCHEMBL19564569 | 0.88 | SLC6A9 (0.48) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL19553320 | 0.86 | SLC6A9 (0.49) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL15809470 | 0.86 | SLC6A9 (0.46) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL15809368 | 0.83 | SLC6A9 (0.45) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL19564630 | 0.83 | GBA1 (0.40) | — | |
| SCHEMBL15827698 | 0.83 | SLC6A9 (0.44) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL15827696 | 0.81 | SLC6A9 (0.50) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL15827691 | 0.81 | SLC6A9 (0.45) | SLC6A9 | |
| SCHEMBL28611274 | 0.81 | SLC6A9 (0.46) | SLC6A9SLC6A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | CACNA1B, CACNA1G, CACNA2D2 | SLC6A9 283/4885SLC6A4 131/4885HRH3 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.